Abstract
While digital phenotyping provides opportunities for unobtrusive, real-time mental health assessments, the integration of its modalities is not trivial due to high dimensionalities and discrepancies in sampling frequencies. We provide an integrated pipeline that solves these issues by transforming all modalities to the same time unit, applying temporal independent component analysis (ICA) to high-dimensional modalities, and fusing the modalities with linear mixed-effects models. We applied our approach to integrate high-quality, daily self-report data with BiAffect keyboard dynamics derived from a clinical suicidality sample of mental health outpatients. Applying the ICA to the self-report data (104 participants, 5712 days of data) revealed components related to well-being, anhedonia, and irritability and social dysfunction. Mixed-effects models (55 participants, 1794 days) showed that less phone movement while typing was associated with more anhedonia (β = -0.12, p = 0.00030). We consider this method to be widely applicable to dense, longitudinal digital phenotyping data.
Competing Interest Statement
CFB is founding director and shareholder of SBG Neuro Ltd. AL is a cofounder of KeyWise AI, previously served on the Medical Board for Buoy Health, and currently serves as a digital psychiatry advisor for Otsuka, USA.
Funding Statement
This study was funded by the European Research Council (101001118). The CLEAR-3 trial was funded by a grant from the National Institute of Mental Health (RF1MH120843). CFB gratefully acknowledges funding from the Wellcome Trust Collaborative Award in Science 215573/Z/19/Z and the Netherlands Organization for Scientific Research Vici Grant No. 17854 and NWO-CAS Grant No. 012-200-013.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of the University of Illinois at Chicago gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Deidentified participant data will be made available on reasonable request to the principal investigator of the CLEAR-3 trial, T.A. Eisenlohr-Moul (temo{at}uic.edu), when provided with an appropriate analysis plan.
